16 Sep New publication highlights the importance of targeting thrombospondin-1 as well as “Don’t eat me”
Check out the new publication by our CEO, Dr. Anthony Schwartz which defines a new mechanism (Schlafen-11) through the CD47/thrombospondin-1 axis that is important for therapeutic resistance in cancer. Morphiex’s MBT-001 is the only drug that blocks “Don’t eat me” and thrombospondin-1 (TSP-1). This study was performed in collaboration with the National Cancer Institute (NCI/NIH) and The Wake Forest School of Medicine.
https://www.frontiersin.org/articles/10.3389/fonc.2019.00994/abstract